Pfizer, Inc. (PFE) Stock Price & How to Invest

Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. Its portfolio spans oncology (a strategic priority, expanded sharply by the acquisition of cancer drugmaker Seagen), vaccines (including pneumococcal franchise Prevnar and its COVID-19 vaccine Comirnaty, partnered with BioNTech), internal medicine and cardiology (such as the Vyndaqel/Vyndamax family and Eliquis, co-marketed with Bristol Myers Squibb), immunology and inflammation, and antivirals (including the COVID treatment Paxlovid). Pfizer makes money selling these drugs to wholesalers, pharmacies, hospitals, and governments worldwide. The company saw an enormous revenue surge from COVID-19 products during the pandemic, then a steep decline as that demand normalized, leaving it to refill growth through its pipeline, oncology expansion, and acquisitions while a wave of patent expirations looms later this decade. Founded in 1849 and headquartered in New York City, Pfizer is a mature, dividend-paying large-cap navigating a post-COVID reset.

Pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap. COVID-19 product revenue (Comirnaty, Paxlovid) has fallen sharply and remains volatile and hard to forecast. The Seagen deal added substantial debt, and large acquisitions carry integration and return risk. Drug pricing pressure, including US policy such as Medicare negotiation, threatens margins on key products. Pipeline setbacks, clinical-trial failures, and regulatory decisions can swing the stock, and the company must continually prove it can generate new blockbusters to sustain growth as legacy drugs mature.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Pfizer, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$60 billion
• Operating margin: ~25%, recovering post-COVID normalization
• Net income (TTM): multi-billion, variable with COVID product swings
• Dividend yield: ~6%, high for large-cap pharma
• P/E (forward): below the market, reflecting growth concerns
• Net debt: elevated after the Seagen acquisition
• R&D spending: ~$10+ billion annually

Pfizer trades at a below-market multiple and a high dividend yield, reflecting investor concern about the post-COVID revenue reset and a looming patent cliff. Its valuation balances substantial cash generation and diversification against questions over whether the pipeline and Seagen-led oncology push can restore durable growth.

If you want PFE exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses PFE naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that show up alongside PFE in the same themes. Worth a look if you're thinking about diversification within a single thesis rather than concentration on one ticker.

There are three common ways to get PFE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (SPHD, DVY, HDV), which spreads the position across many companies. Or build it into a focused thematic basket, so PFE sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where PFE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Pfizer (PFE) is a cash-generative, high-yield pharma navigating a post-COVID reset, using its Seagen-led oncology push, pipeline, and acquisitions to offset products losing exclusivity later this decade. In a portfolio it behaves as a defensive healthcare and dividend-income anchor, with drug-pricing policy, patent expirations, and COVID-revenue volatility as the main swing factors.

Whether PFE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PFE a buy?, and where the stock could go from here in the PFE stock forecast.

For income investors, whether PFE pays a dividend and how the payout looks is covered in does PFE pay a dividend? And to weigh PFE against a peer, read the full side-by-side comparisons: PFE vs LLY and PFE vs NVO.